Baseline characteristics of patients with CP-CML achieving cytogenetic response after TKI
| Characteristic . | No ACAs (n = 473) . | CCA/Ph−(n = 54) . | P . |
|---|---|---|---|
| Median age, y (range) | 47 (15-86) | 59 (25-82) | <.001 |
| Female, no. (%) | 205 (43) | 10 (19) | <.001 |
| Male, no. (%) | 268 (57) | 44 (81) | |
| WBC, median ×109/L (range) | 28 (0.8-342) | 37 (2.5-277) | .71 |
| Hb, median g/L (range) | 12.2 (6.2-16.7) | 12.4 (8.5-16.7) | .22 |
| Platelets, median ×109/L (range) | 331 (28-2928) | 340 (73-1540) | .55 |
| Basophils, median % (range) | 3 (0-19) | 2 (0-16) | .51 |
| Blasts in BM, median % (range) | 2 (0-14) | 1 (0-8) | .89 |
| Type of BCR-ABL transcript, no. (%) | .83 | ||
| e13a2 | 195 (41) | 22 (41) | |
| e14a2 | 189 (40) | 21 (39) | |
| e13a2 and e14a2 | 84 (18) | 10 (18) | |
| Other | 5 (1) | 1 (2) | |
| Sokal score, no. (%) | .01 | ||
| Low | 330 (70) | 27 (50) | |
| Intermediate | 112 (24) | 20 (37) | |
| High | 31 (6) | 7 (13) | |
| Treatment, no. (%) | .04 | ||
| Imatinib 400 mg | 51 (11) | 12 (22) | |
| Imatinib 800 mg | 173 (37) | 15 (28) | |
| Dasatinib | 118 (25) | 8 (15) | |
| Nilotinib | 92 (19) | 15 (28) | |
| Ponatinib | 39 (8) | 4 (7) |
| Characteristic . | No ACAs (n = 473) . | CCA/Ph−(n = 54) . | P . |
|---|---|---|---|
| Median age, y (range) | 47 (15-86) | 59 (25-82) | <.001 |
| Female, no. (%) | 205 (43) | 10 (19) | <.001 |
| Male, no. (%) | 268 (57) | 44 (81) | |
| WBC, median ×109/L (range) | 28 (0.8-342) | 37 (2.5-277) | .71 |
| Hb, median g/L (range) | 12.2 (6.2-16.7) | 12.4 (8.5-16.7) | .22 |
| Platelets, median ×109/L (range) | 331 (28-2928) | 340 (73-1540) | .55 |
| Basophils, median % (range) | 3 (0-19) | 2 (0-16) | .51 |
| Blasts in BM, median % (range) | 2 (0-14) | 1 (0-8) | .89 |
| Type of BCR-ABL transcript, no. (%) | .83 | ||
| e13a2 | 195 (41) | 22 (41) | |
| e14a2 | 189 (40) | 21 (39) | |
| e13a2 and e14a2 | 84 (18) | 10 (18) | |
| Other | 5 (1) | 1 (2) | |
| Sokal score, no. (%) | .01 | ||
| Low | 330 (70) | 27 (50) | |
| Intermediate | 112 (24) | 20 (37) | |
| High | 31 (6) | 7 (13) | |
| Treatment, no. (%) | .04 | ||
| Imatinib 400 mg | 51 (11) | 12 (22) | |
| Imatinib 800 mg | 173 (37) | 15 (28) | |
| Dasatinib | 118 (25) | 8 (15) | |
| Nilotinib | 92 (19) | 15 (28) | |
| Ponatinib | 39 (8) | 4 (7) |
BM, bone marrow; Hb, hemoglobin; WBC, white blood cell count. Other types of BCR-ABL included e1a2, e13a3 and 1 patient with an unknown transcript type.